LeMaitre Vascular (NASDAQ:LMAT) Issues FY 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 2.840-2.940 for the period, compared to the consensus estimate of 3.000. The company issued revenue guidance of $274.3 million-$278.3 million, compared to the consensus revenue estimate of $279.9 million. LeMaitre Vascular also updated its Q3 2026 guidance to 0.660-0.710 EPS.

Analyst Ratings Changes

Several research firms recently commented on LMAT. Wells Fargo & Company dropped their price objective on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Weiss Ratings cut LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, June 30th. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Barrington Research cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Finally, Wall Street Zen lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Four analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $110.60.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock traded up $0.95 on Thursday, hitting $79.95. 249,968 shares of the company traded hands, compared to its average volume of 268,212. LeMaitre Vascular has a 12-month low of $78.65 and a 12-month high of $118.01. The firm’s 50-day simple moving average is $97.08 and its 200 day simple moving average is $99.99. The company has a market cap of $1.83 billion, a P/E ratio of 28.05, a P/E/G ratio of 2.94 and a beta of 0.53. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.90%. The firm had revenue of $70.38 million for the quarter, compared to analysts’ expectations of $71.47 million. During the same quarter in the previous year, the business earned $0.60 EPS. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. Analysts expect that LeMaitre Vascular will post 3 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 3rd. Shareholders of record on Thursday, August 20th will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 1.3%. The ex-dividend date is Thursday, August 20th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 36.90%.

Insider Buying and Selling

In other news, CEO George W. Lemaitre sold 27,881 shares of the company’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $108.69, for a total value of $3,030,385.89. Following the completion of the sale, the chief executive officer owned 1,430,019 shares of the company’s stock, valued at approximately $155,428,765.11. This represents a 1.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Trent G. Kamke sold 2,928 shares of LeMaitre Vascular stock in a transaction on Friday, May 8th. The stock was sold at an average price of $107.00, for a total transaction of $313,296.00. Following the completion of the transaction, the insider owned 3,749 shares in the company, valued at approximately $401,143. The trade was a 43.85% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 7.40% of the company’s stock.

LeMaitre Vascular News Roundup

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Second-quarter revenue increased 9.6% year over year to $70.38 million, while EPS rose to $0.74 from $0.60 a year earlier. The company also declared a quarterly dividend of $0.25 per share, equivalent to an approximately 1.1% annualized yield. LeMaitre Q2 2026 Financial Results
• Neutral Sentiment: Analyst sentiment has become more cautious. Wells Fargo lowered its price target from $104 to $94 while maintaining an Equal Weight rating, and Barrington Research downgraded the shares from Outperform to Market Perform. The average analyst view is now Hold. LeMaitre receives average Hold rating
• Negative Sentiment: Q2 EPS of $0.74 missed the $0.81 consensus estimate, and revenue of $70.38 million came in below the $71.47 million forecast. The earnings shortfall indicates that revenue growth has not translated into results as strongly as investors expected. LeMaitre Q2 earnings and revenues lag estimates
• Negative Sentiment: Management reduced its outlook: third-quarter EPS guidance of $0.66-$0.71 and revenue guidance of $66.3-$68.3 million are below consensus estimates of $0.73 and $69.0 million. Full-year EPS guidance of $2.84-$2.94 and revenue guidance of $274.3-$278.3 million also trail consensus forecasts of $3.00 and $279.9 million. LeMaitre guidance and financial results
• Negative Sentiment: The combination of missed quarterly estimates, lowered guidance, analyst downgrades and a new 12-month low is driving the bearish reaction in LMAT despite continued year-over-year growth and a strong balance-sheet profile. LeMaitre reaches new 12-month low

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Illinois Municipal Retirement Fund lifted its holdings in shares of LeMaitre Vascular by 1.1% in the fourth quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock worth $906,000 after buying an additional 123 shares in the last quarter. NewEdge Advisors LLC grew its stake in LeMaitre Vascular by 4.6% during the fourth quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock valued at $256,000 after acquiring an additional 139 shares in the last quarter. Federated Hermes Inc. grew its stake in LeMaitre Vascular by 0.4% during the second quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock valued at $3,294,000 after acquiring an additional 155 shares in the last quarter. Equitable Holdings Inc. increased its holdings in LeMaitre Vascular by 1.4% in the 4th quarter. Equitable Holdings Inc. now owns 14,469 shares of the medical instruments supplier’s stock valued at $1,173,000 after acquiring an additional 205 shares during the last quarter. Finally, California State Teachers Retirement System lifted its stake in LeMaitre Vascular by 1.7% in the 2nd quarter. California State Teachers Retirement System now owns 18,721 shares of the medical instruments supplier’s stock worth $1,555,000 after purchasing an additional 316 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.